{"id":245928,"date":"2012-03-22T17:58:40","date_gmt":"2012-03-22T17:58:40","guid":{"rendered":"http:\/\/www.eugenesis.com\/amp-applauds-supreme-court-ruling-sees-win-for-patients-and-personalized-medicine\/"},"modified":"2012-03-22T17:58:40","modified_gmt":"2012-03-22T17:58:40","slug":"amp-applauds-supreme-court-ruling-sees-win-for-patients-and-personalized-medicine","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/amp-applauds-supreme-court-ruling-sees-win-for-patients-and-personalized-medicine.php","title":{"rendered":"AMP applauds Supreme Court ruling: Sees win for patients and personalized medicine"},"content":{"rendered":"<p><p>Public  release date: 21-Mar-2012  [ |   E-mail   |  Share    ]  <\/p>\n<p>    Contact: Mary Steele Williams    <a href=\"mailto:mwilliams@amp.org\">mwilliams@amp.org<\/a>    301-634-7321    Association    for Molecular Pathology<\/p>\n<p>    Bethesda, MD, March 21, 2012: \"The Association for Molecular    Pathology (AMP) applauds the U.S. Supreme Court's ruling today    in the case of Mayo Collaborative Services v. Prometheus    Laboratories as a victory for patients and for the advancement    of personalized medicine,\" stated Iris Schrijver, MD, the    Organization's President. AMP, an international professional    society representing more than 2000 physicians, doctoral    scientists, and medical technologists, joined 10 other medical    and healthcare organizations in filing an amicus brief with the    Court in support of Mayo Clinic. AMP is also the lead plaintiff    in Association for Molecular Pathology v. U.S. Patent and    Trademark Office that challenges the validity of patents on two    human genes associated with hereditary breast and ovarian    cancer and is currently under review by the High Court.  <\/p>\n<p>    \"Prometheus acknowledged that physicians can infringe the    patent by merely thinking about the relationship between drug    metabolite levels and patient response,\" asserted Dr.    Schrijver. \"It is encouraging that the Court recognized that    the Prometheus patents neither promote the advancement of    medical practice, nor benefit patient care\".  <\/p>\n<p>    \"In Prometheus, the Court wisely recognized that overly broad    patents can inhibit innovation,\" stated Jennifer Hunt, MD, MEd,    the Organization's President-Elect. \"Establishing a drug    reference range is important, but standard work for laboratory    physicians. Awarding monopolies over the medical use of    natural, biological relationships stifles innovation in true    diagnostic test methods and obstructs improvements for patient    care.\"  <\/p>\n<p>    AMP believes the Supreme Court's reasoning in Mayo v.    Prometheus extends to patents that claim ownership over another    type of natural phenomenon, the biological relationships    between genetic variants and clinical disease. Such    relationships are at the heart of personalized medicine.    \"Patients are increasingly being disadvantaged by gene    correlation patents,\" stated Roger D. Klein, MD, JD, Chair of    AMP's Professional Relations Committee. As an example, Dr.    Klein cited a method patent relating to a variation in a gene    known as FLT3 that is used to qualify some leukemia patients    for bone marrow transplant.  <\/p>\n<p>    Enforcement of the FLT3 patent by a private company has been    forcing physicians and laboratories to split and geographically    distribute irreplaceable bone marrow specimens. \"Splitting    samples creates an additional risk of specimen loss and delays    the receipt of patient results\" stated Dr. Klein. \"In addition,    it interferes with the ability of pathologists to provide    synoptic interpretations involving multiple tests, and prevents    them from implementing cost saving algorithms that limit    unnecessary testing. The Supreme Court's ruling is clearly a    win both for our patients and for personalized healthcare.\"  <\/p>\n<p>    ###  <\/p>\n<p>    ABOUT AMP:  <\/p>\n<p>    The Association for Molecular Pathology (AMP) is an    international medical professional association dedicated to the    advancement, practice, and science of clinical molecular    laboratory medicine and translational research based on the    applications of molecular biology, genetics, and genomics. For    more information, please visit <a href=\"http:\/\/www.amp.org\" rel=\"nofollow\">http:\/\/www.amp.org<\/a>.  <\/p>\n<\/p>\n<p>Continued here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2012-03\/afmp-aas032112.php\" title=\"AMP applauds Supreme Court ruling: Sees win for patients and personalized medicine\">AMP applauds Supreme Court ruling: Sees win for patients and personalized medicine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Public release date: 21-Mar-2012 [ | E-mail | Share ] Contact: Mary Steele Williams <a href=\"mailto:mwilliams@amp.org\">mwilliams@amp.org<\/a> 301-634-7321 Association for Molecular Pathology Bethesda, MD, March 21, 2012: \"The Association for Molecular Pathology (AMP) applauds the U.S. Supreme Court's ruling today in the case of Mayo Collaborative Services v. Prometheus Laboratories as a victory for patients and for the advancement of personalized medicine,\" stated Iris Schrijver, MD, the Organization's President.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/amp-applauds-supreme-court-ruling-sees-win-for-patients-and-personalized-medicine.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577487],"tags":[],"class_list":["post-245928","post","type-post","status-publish","format-standard","hentry","category-pathology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/245928"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=245928"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/245928\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=245928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=245928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=245928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}